IVI’s MISSION is to advance the science and improve the practice of value assessment in healthcare.
IVI’s GOAL is to build a platform that facilitates robust and rigorous patient-centered value assessment of health technologies tailored to the needs and interests of individual decision makers.
The Value Debate
Scientific, technological, and clinical advances are driving a revolution in patient care – but spending on healthcare also continues to increase. Most observers agree that change is needed in order to link healthcare spending to value rather than volume, but determining how to make this link quickly leads to debate and disagreement. What defines value? Value to whom? And how do we measure it?
A New Approach
The Innovation and Value Initiative (IVI) was created to raise the level of discussion regarding value in healthcare and find common ground in the approach to measuring value. The U.S health system is diverse, complex, and ripe for innovation. IVI brings together healthcare leaders from academia, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and patient communities to advance approaches to value that fit the American context.
The IVI Open-Source Development Process
IVI in 2020
PRESS RELEASE: IVI’s Updated RA Model Examines New Treatment Options, Treatment Effects and Cost Estimates
IVI has just released the latest update to the organization's Rheumatoid Arthritis (RA) Value Assessment Model. The updated model now incorporates additional treatment options (triple therapy, Janus Kinase (JAK) inhibitors, sarilumab, and biosimilars), updated treatment [...]
As part of its Value Blueprints series, IVI’s latest research brief grapples with a question prompted by ICER’s recent assessment of RA therapies: Do conventional value assessments address the questions most relevant to real-world decisions [...]
As one of the nine finalists in HealthEconomics.com's inaugural challenge competition to accelerate change in health economics and outcomes research, IVI's Mark Linthicum offered a compelling case for how IVI's Open-Source Value Platform (OSVP) is [...]
IVI offered comments on ICER's recently released Draft Evidence Report examining the cost-effectiveness of Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis. In addition to commenting on the needs for transparency and the impacts of modeling [...]